[New drug combination for medical management of hyperlipemia: clinical study].
Sixteen patients with different kinds of hyperlipidemia were treated with Atroplex (Mg-Chlorphenoxyisobutyrate 350 mg, Mesoinositol-Hexanicotinate 250 mg), a new serum lipid decreasing drug. Within an interval of 60 days' standard treatment of 3 tablets of Atroplex, the serum level of cholesterol was reduced by 16-20% and that of triglycerides by 36-49%. This significant effect was obvious over the whole period of treatment. According to the compound of Clofibrate, Atroplex interfered with the anticoagulant treatment with phenprocoumon. In spite of this an AC-therapy is possible during the Atroplex medication, if the AC doses are reduced by 30-50%.
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D002995:Clofibric Acid; D004338:Drug Combinations; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007294:Inositol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D004338:Drug Combinations; D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D014280:Triglycerides; D007294:Inositol; D002995:Clofibric Acid; C015694:magnesium chlorphenoxyisobutyrate, mesoinositol hexanicotinate drug combination; D002784:Cholesterol; D002994:Clofibrate
Eine neue Wirkstoffkombination zur medikamentösen Behandlung der Hyperlipidämien: Klinische Studie.